DCOY — Decoy Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Delta Air Lines, Crypto stocks, Solar stocks
U.S. STOCKS ON THE MOVE-Alcoa, WD-40, Broadcom
Salarius Pharma falls as FDA puts cancer drug trial on partial clinical hold
Brief: Salarius Pharmaceuticals says FDA Placing Clinical Trial Evaluating Seclidemstat (Sp-2577) In Combination With Azacitidine On Partial Clinical Hold
Brief: Salarius Pharmaceuticals Announces 1-For-8 Reverse Stock Split
Salarius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Salarius Pharmaceuticals Reports Q4 And Full Year 2023 Results
Brief: Salarius Pharmaceuticals Q4 Net Income USD -900 Thousand
Brief: Salarius Provides Update On Strategic Review Process
Brief: Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial To Treat Hematologic Cancers Resumes Patient Enrollment
Brief: Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Brief: Salarius Pharmaceuticals Receives Notice Of Delisting
Brief: Salarius Pharmaceuticals, Inc. Q2 EPS USD -1.43
Salarius Pharmaceuticals Inc expected to post a loss of $1.30 a share - Earnings Preview
Brief: Salarius Pharmaceuticals Announces Closing Of $6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Brief: Salarius Pharmaceuticals Announces $6 Million Private Placement
Salarius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Salarius Pharmaceuticals Reports Quarterly Loss Per Common Share Basic And Diluted Of $2.23
U.S. STOCKS ON THE MOVE-Airbnb, Y-mAbs Therapeutics, Neuronetics